An effect of the PAI-1 4G/5G polymorphism on cholesterol levels may explain conflicting associations with myocardial infarction and stroke

Cerebrovascular Diseases

Volumn 22, Issue 2-3, 2006, Pages 191-195

  Boncoraglio, Giorgio B ^a   Bodini, Antonella ^b   Brambilla, Carla ^b   Carriero, Maria Rita ^a   Ciusani, Emilio ^a   Parati, Eugenio A ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b CNR   (Italy)

Author keywords

Cerebral ischemia; Cholesterol; Plasminogen activator inhibitor 1 polymorphism; Triglycerides

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL CONTRACEPTION; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO; SMOKING; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC;

EID: 33746348915     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093604     Document Type: Article

References (21)

1. Kohler HP, Grant PJ: Plasminogen-activator inhibitor type I and coronary artery disease. N Engl J Med 2000;342:1792-1801.
2. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000;95:1517-1532.
3. Voetsch B, Loscalzo J: Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol 2004;24:216-229.
4. van der Bom JG, Bots ML, Haverkate F, Kluft C, Grobbee DE: The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 2003;101:1841-1844.
5. Roest M, Banga JD: Genetic make-up for increased PAI-1 expression protects against stroke. Stroke 2003;34:2828-2829.
6. Jood K, Ladenvall P, Tjarnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, Blomstrand C, Jern C: Fibrinolytic gene polymorphism and ischemic stroke. Stroke 2005;36:2077-2081.
7. Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S, Parati E, Croci D, Boiardi A, Salmaggi A: Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 2004;10:1312-1317.
8. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
9. Chen CH, Eng HL, Chang CJ, Tsai TT, Lai ML, Chen HY, Liu CJ, Lin TM: 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med 2003;142:100-105.
10. Bang CO, Park HK, Ahn MY, Shin HK, Hwang KY, Hong SY: 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis 2001;11:294-299.
11. Kain K, Young J, Bamford J, Bavington J, Grant PJ, Catto AJ: Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke. Cerebrovasc Dis 2002;14:77-83.
12. Wiklund PG, Nilsson L, Ardnor SN, Eriksson P, Johansson L, Stegmayr B, Hamsten A, Holmberg D, Asplund K: Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005;36:1661-1665.
13. Eriksson P, Nilsson L, Karpe F, Hamsten A: Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998;18:20-26.
14. Davey Smith G, Ebrahim S: What can Mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 2005;330:1076-1079.
15. Donnan GA, Davis SM: Stroke and cholesterol: weakness of risk versus strength of therapy. Stroke 2004;35:1526.
16. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F: Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation 2002;105:2632-2637.
17. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG: Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 1996;94:2057-2063.
18. Armstead WM, Cines DB, Higazi AA: Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 2005;36:2265-2269.
19. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P, International HapMap Consortium: a haplotype map of the human genome. Nature 2005;437:1299-1320.
20. National Center for Biotechnology Information: OMIM: online Mendelian inheritance in man. http://www.ncbi.nlm.nih.gov/omim.
21. Campo S, Sardo MA, Trimarchi G, Bonaiuto M, Fontana L, Castaldo M, Bonaiuto A, Saitta C, Bitto A, Manduca B, Riggio S, Saitta A: Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 2004;39:1089-1094.